Literature DB >> 15674365

Dysregulated expression of the major telomerase components in leukaemic stem cells.

M W Drummond1, S F Hoare, A Monaghan, S M Graham, M J Alcorn, W N Keith, T L Holyoake.   

Abstract

Telomere loss is rapid during the progression of chronic myeloid leukaemia (CML) and correlates with prognosis. We therefore sought to measure expression of the major telomerase components (hTR and hTERT) in CD34+ cells from CML patients and normal controls, to determine if their altered expression may contribute to telomere attrition in vivo. High-purity (median 94.1%) BCR-ABL+ CD34+ cells from CML (n=16) and non-CML (n=14) patients were used. CML samples had a small increase in telomerase activity (TA) compared to normal samples (approximately 1.5-fold, P=0.004), which was inversely correlated with the percentage of G0 cells (P=0.02) suggesting TA may not be elevated on a cell-to-cell basis in CML. Consistent with this, hTERT mRNA expression was not significantly elevated; however, altered mRNA splicing appeared to play a significant role in determining overall full length, functional hTERT levels. Interestingly, Q-RT-PCR for hTR demonstrated a mean five-fold reduction in levels in the chronic phase (CP) CML samples (P=0.002), raising the possibility that telomere homeostasis is disrupted in CML. In summary, the molecular events regulating telomerase gene expression and telomere maintenance during the CP of CML may influence the disease progression observed in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674365     DOI: 10.1038/sj.leu.2403616

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.

Authors:  Maroun Karam; Morgan Thenoz; Valérie Capraro; Jean-Philippe Robin; Christiane Pinatel; Agnès Lancon; Perrine Galia; David Sibon; Xavier Thomas; Sophie Ducastelle-Lepretre; Franck Nicolini; Mohamed El-Hamri; Youcef Chelghoun; Eric Wattel; Franck Mortreux
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 2.  Telomere biology in hematopoiesis and stem cell transplantation.

Authors:  Shahinaz M Gadalla; Sharon A Savage
Journal:  Blood Rev       Date:  2011-07-20       Impact factor: 8.250

3.  Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Authors:  Claudia Bruedigam; Frederik O Bagger; Florian H Heidel; Catherine Paine Kuhn; Solene Guignes; Axia Song; Rebecca Austin; Therese Vu; Erwin Lee; Sarbjit Riyat; Andrew S Moore; Richard B Lock; Lars Bullinger; Geoffrey R Hill; Scott A Armstrong; David A Williams; Steven W Lane
Journal:  Cell Stem Cell       Date:  2014-12-04       Impact factor: 24.633

4.  Proliferation and pluripotency potential of ectomesenchymal cells derived from first branchial arch.

Authors:  Yunfeng Lin; Zhengbin Yan; Lei Liu; Ju Qiao; Wei Jing; Ling Wu; Xizhe Chen; Zhiyong Li; Wei Tang; Xiaohui Zheng; Weidong Tian
Journal:  Cell Prolif       Date:  2006-04       Impact factor: 6.831

5.  Chronic myeloid leukemia stem cell biology.

Authors:  Leslie A Crews; Catriona H M Jamieson
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

6.  Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia.

Authors:  Beate Vajen; Kathrin Thomay; Brigitte Schlegelberger
Journal:  Cancers (Basel)       Date:  2013-07-04       Impact factor: 6.639

7.  Establishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement.

Authors:  Qian Wang; Lin Zhuang; Pei Li; Qiang Niu; Ping Zhu; Miao-Xia He; Hui Jiang; Chang-Cheng Liu; Min-Jun Wang; Li Chen; Hui Cheng; Yan Ma; Xiao-Xia Hu; Yi-Ping Hu; Xiao-Ping Xu
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.